Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.
2.

Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer.

Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Ingebriktsen LM, Fassina A, Taskén KA, Mills IG, Donnem T, Bremnes RM, Busund LT.

Sci Rep. 2019 Jul 23;9(1):10662. doi: 10.1038/s41598-019-47234-0.

3.

Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC.

Kilvaer TK, Rakaee M, Hellevik T, Vik J, Petris L, Donnem T, Strell C, Ostman A, Busund LR, Martinez-Zubiaurre I.

Sci Rep. 2019 Jul 15;9(1):10163. doi: 10.1038/s41598-019-46510-3.

4.

Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.

Rakaee M, Busund LR, Jamaly S, Paulsen EE, Richardsen E, Andersen S, Al-Saad S, Bremnes RM, Donnem T, Kilvaer TK.

Neoplasia. 2019 Mar;21(3):282-293. doi: 10.1016/j.neo.2019.01.005. Epub 2019 Feb 10.

5.

MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer.

Richardsen E, Andersen S, Melbø-Jørgensen C, Rakaee M, Ness N, Al-Saad S, Nordby Y, Pedersen MI, Dønnem T, Bremnes RM, Busund LT.

Sci Rep. 2019 Jan 23;9(1):386. doi: 10.1038/s41598-018-36854-7.

6.

Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression.

Grindstad T, Richardsen E, Andersen S, Skjefstad K, Rakaee Khanehkenari M, Donnem T, Ness N, Nordby Y, Bremnes RM, Al-Saad S, Busund LT.

Sci Rep. 2018 Jul 27;8(1):11358. doi: 10.1038/s41598-018-29520-5.

7.

Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.

Rakaee M, Kilvaer TK, Dalen SM, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT.

Hum Pathol. 2018 Sep;79:188-198. doi: 10.1016/j.humpath.2018.05.017. Epub 2018 Jun 6.

PMID:
29885403
8.

A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer.

Skjefstad K, Johannessen C, Grindstad T, Kilvaer T, Paulsen EE, Pedersen M, Donnem T, Andersen S, Bremnes R, Richardsen E, Al-Saad S, Busund LT.

Sci Rep. 2018 Jun 4;8(1):8549. doi: 10.1038/s41598-018-26864-w.

9.

Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.

Kilvaer TK, Rakaee M, Hellevik T, Østman A, Strell C, Bremnes RM, Busund LT, Dønnem T, Martinez-Zubiaurre I.

PLoS One. 2018 Feb 7;13(2):e0192157. doi: 10.1371/journal.pone.0192157. eCollection 2018.

10.

LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival.

Hald SM, Rakaee M, Martinez I, Richardsen E, Al-Saad S, Paulsen EE, Blix ES, Kilvaer T, Andersen S, Busund LT, Bremnes RM, Donnem T.

Clin Lung Cancer. 2018 May;19(3):249-259.e2. doi: 10.1016/j.cllc.2017.12.001. Epub 2017 Dec 11.

PMID:
29396238
11.

Corrigendum to "Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer" [Steroids 113 (2016) 5-13].

Skjefstad K, Grindstad T, Rakaee Khanehkenari M, Richardsen E, Donnem T, Kilvaer T, Andersen S, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2018 Feb;130:36-37. doi: 10.1016/j.steroids.2017.11.010. Epub 2017 Dec 19. No abstract available.

PMID:
29273210
12.

Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.

Andersen S, Richardsen E, Rakaee M, Bertilsson H, Bremnes R, Børset M, Busund LT, Slørdahl T.

PLoS One. 2017 Nov 30;12(11):e0189000. doi: 10.1371/journal.pone.0189000. eCollection 2017.

13.

High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?

Nordby Y, Richardsen E, Ness N, Donnem T, Patel HRH, Busund LT, Bremnes RM, Andersen S.

Sci Rep. 2017 Nov 24;7(1):16308. doi: 10.1038/s41598-017-16556-2.

14.

Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.

Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Grindstad T, Movik I, Dønnem T, Bremnes R, Busund LT.

PLoS One. 2017 Nov 15;12(11):e0186852. doi: 10.1371/journal.pone.0186852. eCollection 2017.

15.

Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.

Johannessen C, Moi L, Kiselev Y, Pedersen MI, Dalen SM, Braaten T, Busund LT.

PLoS One. 2017 Oct 26;12(10):e0186658. doi: 10.1371/journal.pone.0186658. eCollection 2017.

16.

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.

Al-Saad S, Richardsen E, Kilvaer TK, Donnem T, Andersen S, Khanehkenari M, Bremnes RM, Busund LT.

PLoS One. 2017 Jul 25;12(7):e0181527. doi: 10.1371/journal.pone.0181527. eCollection 2017.

17.

CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.

Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund LT, Bremnes RM, Donnem T.

Cancer Immunol Immunother. 2017 Nov;66(11):1449-1461. doi: 10.1007/s00262-017-2039-2. Epub 2017 Jul 13.

18.

Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.

Duell EJ, Lujan-Barroso L, Sala N, Deitz McElyea S, Overvad K, Tjonneland A, Olsen A, Weiderpass E, Busund LT, Moi L, Muller D, Vineis P, Aune D, Matullo G, Naccarati A, Panico S, Tagliabue G, Tumino R, Palli D, Kaaks R, Katzke VA, Boeing H, Bueno-de-Mesquita HBA, Peeters PH, Trichopoulou A, Lagiou P, Kotanidou A, Travis RC, Wareham N, Khaw KT, Ramon Quiros J, Rodríguez-Barranco M, Dorronsoro M, Chirlaque MD, Ardanaz E, Severi G, Boutron-Ruault MC, Rebours V, Brennan P, Gunter M, Scelo G, Cote G, Sherman S, Korc M.

Int J Cancer. 2017 Sep 1;141(5):905-915. doi: 10.1002/ijc.30790. Epub 2017 Jun 12.

19.

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.

Ness N, Andersen S, Khanehkenari MR, Nordbakken CV, Valkov A, Paulsen EE, Nordby Y, Bremnes RM, Donnem T, Busund LT, Richardsen E.

Oncotarget. 2017 Apr 18;8(16):26789-26801. doi: 10.18632/oncotarget.15817.

20.

High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA.

Int J Cancer. 2017 Jul 1;141(1):184-190. doi: 10.1002/ijc.30726. Epub 2017 Apr 21.

21.

High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.

Nordby Y, Richardsen E, Rakaee M, Ness N, Donnem T, Patel HR, Busund LT, Bremnes RM, Andersen S.

Sci Rep. 2017 Feb 24;7:43378. doi: 10.1038/srep43378.

22.

Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2016 Nov 24;16(1):916. No abstract available.

23.

Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.

Andersen S, Richardsen E, Moi L, Donnem T, Nordby Y, Ness N, Holman ME, Bremnes RM, Busund LT.

Sci Rep. 2016 Nov 8;6:36573. doi: 10.1038/srep36573.

24.

Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.

Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT, Bremnes RM, Donnem T.

Clin Lung Cancer. 2017 Mar;18(2):220-233.e8. doi: 10.1016/j.cllc.2016.09.009. Epub 2016 Oct 5.

25.

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer.

Rakaee M, Busund LT, Paulsen EE, Richardsen E, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Kilvaer TK.

Oncotarget. 2016 Nov 1;7(44):72184-72196. doi: 10.18632/oncotarget.12360.

26.

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome.

Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund LT, Bremnes RM, Richardsen E.

Sci Rep. 2016 Sep 9;6:33114. doi: 10.1038/srep33114.

27.

Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer.

Skjefstad K, Grindstad T, Khanehkenari MR, Richardsen E, Donnem T, Kilvaer T, Andersen S, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2016 Sep;113:5-13. doi: 10.1016/j.steroids.2016.05.008. Epub 2016 May 24. Erratum in: Steroids. 2017 Dec 19;:.

PMID:
27234503
28.

The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival.

Kilvaer TK, Paulsen EE, Khanehkenari MR, Al-Saad S, Johansen RM, Al-Shibli K, Bremnes RM, Busund LT, Donnem T.

Br J Cancer. 2016 May 10;114(10):1145-51. doi: 10.1038/bjc.2016.92. Epub 2016 Apr 7.

29.

Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?

Bremnes RM, Donnem T, Busund LT.

Ann Transl Med. 2016 Apr;4(7):142. doi: 10.21037/atm.2016.03.28. No abstract available.

30.

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.

Bremnes RM, Busund LT, Kilvær TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC, Dønnem T.

J Thorac Oncol. 2016 Jun;11(6):789-800. doi: 10.1016/j.jtho.2016.01.015. Epub 2016 Feb 1. Review.

31.

CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.

Paulsen EE, Kilvaer T, Khanehkenari MR, Maurseth RJ, Al-Saad S, Hald SM, Al-Shibli K, Andersen S, Richardsen E, Busund LT, Bremnes R, Donnem T.

Neoplasia. 2015 Nov;17(11):839-48. doi: 10.1016/j.neo.2015.11.004.

32.

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM.

Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. Review.

PMID:
26578726
33.

Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Kilvaer TK, Paulsen EE, Hald SM, Wilsgaard T, Bremnes RM, Busund LT, Donnem T.

PLoS One. 2015 Aug 25;10(8):e0132481. doi: 10.1371/journal.pone.0132481. eCollection 2015. Review.

34.

The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.

Richardsen E, Ness N, Melbø-Jørgensen C, Johannesen C, Grindstad T, Nordbakken C, Al-Saad S, Andersen S, Dønnem T, Nordby Y, Bremnes RM, Busund LT.

Am J Pathol. 2015 Oct;185(10):2722-30. doi: 10.1016/j.ajpath.2015.06.013. Epub 2015 Aug 10.

PMID:
26272362
35.

Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.

Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbø-Jørgensen C, Patel HR, Dønnem T, Busund LT, Bremnes RM.

Prostate. 2015 Nov;75(15):1682-93. doi: 10.1002/pros.23048. Epub 2015 Aug 13.

PMID:
26268996
36.

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.

Kilvaer TK, Khanehkenari MR, Hellevik T, Al-Saad S, Paulsen EE, Bremnes RM, Busund LT, Donnem T, Martinez IZ.

PLoS One. 2015 Aug 7;10(8):e0134965. doi: 10.1371/journal.pone.0134965. eCollection 2015.

37.

Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure.

Andersen S, Solstad Ø, Moi L, Donnem T, Eilertsen M, Nordby Y, Ness N, Richardsen E, Busund LT, Bremnes RM.

Urol Oncol. 2015 Aug;33(8):338.e9-17. doi: 10.1016/j.urolonc.2015.05.013. Epub 2015 Jun 8.

PMID:
26066969
38.

Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer.

Pøhl M, Olsen KE, Holst R, Donnem T, Busund LT, Bremnes RM, Al-Saad S, Andersen S, Richardsen E, Ditzel HJ, Hansen O.

Acta Oncol. 2016;55(2):167-77. doi: 10.3109/0284186X.2015.1049291. Epub 2015 Jun 9.

PMID:
26057535
39.

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2015 May 29;15:441. doi: 10.1186/s12885-015-1446-z. Erratum in: BMC Cancer. 2016 Nov 24;16(1):916.

40.

High progesterone receptor expression in prostate cancer is associated with clinical failure.

Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbø-Jørgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E.

PLoS One. 2015 Feb 27;10(2):e0116691. doi: 10.1371/journal.pone.0116691. eCollection 2015.

41.

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT.

Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13.

42.

The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival.

Skjefstad K, Richardsen E, Donnem T, Andersen S, Kiselev Y, Grindstad T, Hald SM, Al-Shibli K, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2015 Jun;98:29-36. doi: 10.1016/j.steroids.2015.01.020. Epub 2015 Feb 7.

PMID:
25668612
43.

Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality.

Richardsen E, Uglehus RD, Johnsen SH, Busund LT.

Anticancer Res. 2015 Feb;35(2):865-74.

PMID:
25667468
44.

Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.

Melbø-Jørgensen C, Ness N, Andersen S, Valkov A, Dønnem T, Al-Saad S, Kiselev Y, Berg T, Nordby Y, Bremnes RM, Busund LT, Richardsen E.

PLoS One. 2014 Nov 17;9(11):e113039. doi: 10.1371/journal.pone.0113039. eCollection 2014.

45.

Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival.

Eilertsen M, Andersen S, Al-Saad S, Kiselev Y, Donnem T, Stenvold H, Pettersen I, Al-Shibli K, Richardsen E, Busund LT, Bremnes RM.

PLoS One. 2014 Sep 16;9(9):e105038. doi: 10.1371/journal.pone.0105038. eCollection 2014.

46.

Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer.

Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E.

Prostate. 2014 Oct;74(14):1452-61. doi: 10.1002/pros.22862. Epub 2014 Aug 11.

PMID:
25111810
47.

Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.

Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, Al-Shibli K, Donnem T, Bertilsson H, Busund LT, Angelsen A, Bremnes RM.

BMC Urol. 2014 Jun 14;14:49. doi: 10.1186/1471-2490-14-49.

48.

Stage and tissue-specific prognostic impact of miR-182 in NSCLC.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Busund LT, Bremnes RM.

BMC Cancer. 2014 Feb 27;14:138. doi: 10.1186/1471-2407-14-138.

49.

High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Valkov A, Pedersen MI, Busund LT, Bremnes RM.

BMC Clin Pathol. 2014 Feb 13;14(1):9. doi: 10.1186/1472-6890-14-9.

50.

The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund LT, Donnem T.

BMC Clin Pathol. 2014 Jan 20;14(1):5. doi: 10.1186/1472-6890-14-5.

Supplemental Content

Loading ...
Support Center